利安达会计师事务所(特殊普通合伙) 宁波索宝蛋白科技股份有限公司 审计报告 2024 年度 目 求 | | | 页次 | | --- | --- | --- | | - | 审计报告 | 1-5 | | ו ו | 合并资产负债表 | 1-2 | | 三、 | 合并利润表 | 3 | | 四、 | 合并现金流量表 | प | | 五、 | 合并股东权益变动表 | 5-6 | | 六、 | 母公司资产负债表 | 7-8 | | 七、 | 母公司利润表 | 9 | | 八、 | 母公司现金流量表 | 10 | | 九、 | 母公司股东权益变动表 | 11-12 | | 十、财务报表附注 | | 1-118 | 一、审计意见 我们审计了宁波索宝蛋白科技股份有限公司(以下简称"索宝蛋白公司") 财务报表,包括2024年12月31日的合并及母公司资产负债表,2024年度的合 并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表以 及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了索宝蛋白公司 2024年 12月 31 日合并及母公司的财务状况以及 202 ...

利安达会计师事务所(特殊普通合伙) 关于宁波索宝蛋白科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 目 录 | | 页次 | | --- | --- | | 一、专项审核报告 | 1-2 | | 二、附表 | 3 | 关于宁波索宝蛋白科技股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 利安达专字[2025]第 0069 号 宁波索宝蛋白科技股份有限公司全体股东: 委托单位:宁波索宝蛋白科技股份有限公司 审计单位:利安达会计师事务所(特殊普通合伙) 联系电话:(010) 85886680 传真号码:(010) 85886690 网 网 址： http://www.Reanda.com 否由具有执业许可 您可使用手机"扫一扫"或进入"注册会计师行业统一监管实 我们接受委托,在审计了宁波索宝蛋自科技股份有限公司(以下简称"索宝 蛋白公司")2024年12月31日合并及母公司的资产负债表,2024年度的合并 及母公司利润表、合并及母公司现金流量表和合并及母公司股东权益变动表以及 财务报表附注的基础上,对后附的《上市公司 2024年度非经营性资金占用及其 他关 ...

Financial Performance - The company's revenue for 2024 was CNY 1,555,382,604, a decrease of 11.04% compared to CNY 1,748,322,154 in 2023[23]. - Net profit attributable to shareholders for 2024 was CNY 121,180,733.7, down 16.99% from CNY 145,983,710.6 in 2023[23]. - Basic earnings per share for 2024 decreased by 38.24% to CNY 0.63 from CNY 1.02 in 2023[24]. - The weighted average return on equity dropped to 6.44% in 2024, down 9.86 percentage points from 16.30% in 2023[24]. - The net cash flow from operating activities for 2024 was CNY 147,685,519.0, an increase of 2.65% compared to CNY 143,870,380.9 in 2023[23]. - Total assets at the end of 2024 were CNY 2,084,649,913, a decrease of 4.63% from CNY 2,185,778,622 at the end of 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 109,594,020.1, down 23.66% from CNY 143,565,432.7 in 2023[23]. - The company reported a net loss from the disposal of non-current assets of CNY -2,891,837.19 in 2024[29]. - Government subsidies recognized in 2024 amounted to CNY 4,740,807.87, compared to CNY 15,667,453.40 in 2023[30]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares, totaling RMB 57,437,731.50, which represents 47.40% of the net profit attributable to shareholders for the year 2024[6]. - As of December 31, 2024, the company's undistributed profits amounted to RMB 58,972,527.07[6]. - The total share capital of the company is 191,459,105 shares as of the dividend distribution date[6]. - The cash dividend amount (including tax) for the reporting period is CNY 57,437,731.50, which accounts for 47.40% of the net profit attributable to ordinary shareholders in the consolidated financial statements[152]. - The cumulative cash dividend amount over the last three accounting years (including tax) is CNY 196,245,575.50, with an average annual net profit of CNY 143,724,632.73, resulting in a cash dividend ratio of 136.54%[154]. Corporate Governance - The company has established a robust governance structure, ensuring compliance with legal and regulatory requirements, and promoting transparency in information disclosure[115]. - The company has held nine board meetings and seven supervisory meetings during the reporting period, adhering to governance protocols[116]. - The company emphasizes investor relations management, enhancing communication through various channels to protect investor rights[117]. - During the reporting period, the company maintained a good level of insider information management, with no incidents of information leakage or insider trading[117]. - The company held three shareholder meetings during the reporting period, with all resolutions passed successfully[119]. - The total remuneration for directors and senior management during the reporting period amounted to 730.22 million yuan[121]. - The company has seen changes in its board, with several directors and supervisors leaving due to re-election or resignation[131]. - The company has independent directors serving in various other companies, enhancing governance and oversight[127]. - The company has established a remuneration management system for directors and supervisors, approved by the shareholders' meeting[129]. - The company has seen a turnover in its management team, with several key personnel changes during the reporting period[130]. Market and Product Development - The company is focusing on developing functional proteins and health foods in response to increasing consumer demand for natural and organic products[43]. - The company is positioned as a leading player in the soybean protein industry with a complete deep processing industrial chain and a diverse product line[47]. - The company is actively involved in the development of new products and technologies, collaborating with research institutions on key projects[52]. - The company aims to enhance its high-end manufacturing capabilities through a dedicated planning center and strategic consultations[38]. - The company plans to increase R&D investment to drive innovation in soybean protein processing technology and develop high-value-added products[92]. - The company aims to expand its presence in the plant-based food market, particularly in plant meat and plant milk sectors, by strengthening partnerships with domestic and international companies[92]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $150 million allocated for potential mergers and acquisitions[122]. Environmental Responsibility - The company has invested CNY 3,764.86 million in environmental protection during the reporting period[161]. - The company's wastewater treatment plant has a processing capacity of 120 m³/d, meeting the tertiary urban discharge standards[165]. - The biotechnology division's wastewater treatment plant has a current capacity of 4500 m³/d, with an expansion project to 7500 m³/d underway[165]. - The company operates two 75T coal powder boilers, utilizing a dust removal system and a flue gas treatment process that ensures compliance with emission standards[166]. - The company has obtained pollution discharge permits for its subsidiaries, with actual emissions consistently below permitted limits[167]. - The company has established emergency response plans for environmental incidents, with regular training and drills conducted[168]. - The company has implemented a self-monitoring scheme for environmental compliance, with no exceedances reported in 2024[169]. - The company has constructed a 910 kW distributed rooftop photovoltaic power station to reduce carbon emissions[171]. - The wastewater treatment facilities are operating normally, ensuring pollutant discharge meets regulatory standards[165]. - The company is actively engaged in environmental protection and has committed to disclosing environmental information for 2024[170]. Risks and Challenges - The company has outlined various industry and policy risks in its annual report, urging investors to pay attention[9]. - The company faces risks from significant fluctuations in the RMB exchange rate, which could adversely impact its export business priced in USD[106]. - The company is expanding its high-end soybean protein production base, which will increase operational scale and management complexity, raising the risk of internal control failures[107]. - The actual controller holds a 43.22% stake in the company, which may lead to risks associated with concentrated control and potential improper decision-making[109]. - The company's fundraising projects are expected to enhance core competitiveness and profitability, but risks exist if projects do not meet expected outcomes due to management or market changes[111]. - Increased fixed asset depreciation from fundraising projects may negatively impact financial performance if the projects do not generate anticipated benefits[112]. Strategic Initiatives - The company is implementing lean production management to improve order fulfillment rates and enhance production efficiency[93]. - The company is focusing on strategic procurement to optimize purchasing channels and reduce costs for key raw materials like soybeans and coal[94]. - The company is enhancing its food safety control system to mitigate risks associated with food safety and quality issues[100]. - The company is committed to sustainable development by optimizing production processes to reduce energy consumption and emissions[92]. - The company will strengthen technology research and development investment to enhance customer service capabilities[195]. - The company aims to improve operational and management levels to enhance overall profitability in the coming years[197]. Shareholder Commitments - The controlling shareholder, Shandong Wandefu Industrial Group, has made similar commitments regarding share management and transfer restrictions for 36 months post-listing[182]. - The closing price of the company's stock has been consistently lower than the IPO price, leading to an automatic extension of the lock-up period by 6 months[183]. - The actual controller Liu Jishan has committed not to transfer or delegate management of shares held prior to the IPO for 36 months[184]. - After the lock-up period, any reduction in shareholding must not be below the IPO price, with an automatic extension of the lock-up period if the stock price remains below the IPO price for 20 consecutive trading days[186]. - Major shareholders have committed to not reducing their holdings below the IPO price during the lock-up period and for two years thereafter[187]. - The company will compensate for any economic losses incurred by investors due to non-compliance with shareholding commitments[188].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 391,920,304.59, a decrease of 0.26% compared to the same period last year[4] - Net profit attributable to shareholders increased by 22.41% to CNY 44,476,092.41, while the net profit after deducting non-recurring gains and losses rose by 26.14% to CNY 41,860,638.10[4] - The basic earnings per share for the period was CNY 0.23, reflecting a growth of 21.05% year-on-year[6] - The company reported a significant increase in net profit despite a slight decline in operating revenue, indicating improved operational efficiency[4] - Total operating revenue for Q1 2025 was ¥391,920,304.59, a slight decrease of 0.26% compared to ¥392,958,453.13 in Q1 2024[16] - Net profit for Q1 2025 increased by 22.43% to ¥44,476,092.41 compared to ¥36,333,953.10 in Q1 2024[17] - Basic and diluted earnings per share for Q1 2025 were both ¥0.23, up from ¥0.19 in Q1 2024[18] - The company’s total comprehensive income for Q1 2025 was ¥44,479,985.44, compared to ¥36,333,953.10 in Q1 2024[18] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 2,137,494,093.98, an increase of 2.53% from the end of the previous year[6] - As of March 31, 2025, the total assets of the company amounted to RMB 2,137,494,093.98, an increase from RMB 2,084,649,913.94 as of December 31, 2024, reflecting a growth of approximately 2.53%[12] - The company's current assets totaled RMB 1,328,511,118.23, compared to RMB 1,296,925,659.65 at the end of 2024, indicating an increase of about 2.63%[13] - The total liabilities of the company were RMB 218,595,907.46, up from RMB 210,231,712.86, reflecting an increase of about 1.7%[14] - The owner's equity reached RMB 1,918,898,186.52, compared to RMB 1,874,418,201.08, indicating a growth of approximately 2.37%[15] Cash Flow - The net cash flow from operating activities was negative at CNY -55,884,419.94, primarily due to increased raw material purchases[8] - Cash flow from operating activities showed a net outflow of ¥55,884,419.94 in Q1 2025, compared to a net inflow of ¥18,553,701.83 in Q1 2024[20] - Cash flow from investing activities resulted in a net outflow of ¥141,413,268.38 in Q1 2025, compared to a larger outflow of ¥675,349,522.92 in Q1 2024[21] - Cash and cash equivalents decreased to RMB 124,349,141.98 from RMB 320,026,347.41, representing a decline of approximately 61.1%[12] - Cash and cash equivalents at the end of Q1 2025 were ¥124,344,141.98, down from ¥350,787,028.79 at the end of Q1 2024[21] Shareholder Information - The top ten shareholders held a total of 43.2% of the company's shares, with Shandong Wandefu Industrial Group Co., Ltd. being the largest shareholder[10] - There were no significant changes in the top 10 shareholders or their shareholding status during the reporting period[12] Other Information - The company received government subsidies amounting to CNY 307,430.60 during the reporting period[7] - Non-recurring gains and losses totaled CNY 2,615,454.31, with significant contributions from fair value changes of financial assets[8] - The company has ongoing investments in new technologies and market expansion strategies, although specific details were not provided in the content[12] - The company reported other income of ¥176,541.05 in Q1 2025, an increase from ¥124,315.89 in Q1 2024[17] - The company experienced a foreign exchange impact of ¥1,740,972.57 on cash and cash equivalents in Q1 2025[21] - The company's cash flow from operating activities showed a net outflow of ¥55,884,419.94 in Q1 2025, compared to a net inflow of ¥18,553,701.83 in Q1 2024[20]

| 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例(%) | (万股) | | 济南财金复星惟实股权投资基金合伙企业(有限合伙) | 1347.30 | 12.68 | 新进 | | 上海复星创富投资管理股份有限公司-宁波梅山保税港区复星 | | | | | 惟盈股权投资基金合伙企业(有限合伙) | 1347.30 | 12.68 | 新进 | | 邦吉(上海)管理有限公司 | 717.97 | 6.76 | 新进 | | 胡安智 | 491.01 | 4.62 | 新进 | | 上海至辰资产管理有限公司-镕至(东营)股权投资基金合伙企 | | | | | 业(有限合伙) | 466.67 | 4.39 | 新进 | | 宁波合信投资合伙企业(有限合伙) | 390.71 | 3.68 | 新进 | | 宁波东睿投资合伙企业(有限合伙) | 293.00 | 2.76 | 新进 | | 青岛闫泰企业管理咨询中心(有限合伙) | 250.32 | 2.36 | 新进 | | 徐广成 | 88.64 | 0.83 | 新进 | | ...

2023年12月15日，索宝蛋白在上交所主板上市，发行股份数量为4,786.48万股，无老股转让，全部为公 开发行新股，发行价格为21.29元/股，保荐机构（主承销商）为东吴证券股份有限公司，保荐代表人为 庞家兴、祁俊伟；联席主承销商为南京证券（601990）股份有限公司。目前公司股价处于破发状态。 索宝蛋白本次发行募集资金总额101,904.16万元，募集资金净额97,945.57万元。索宝蛋白最终募集资金 净额比原计划多42,487.31万元。索宝蛋白2023年12月8日发布的首次公开发行股票并在主板上市招股说 明书显示，公司拟募集资金55,458.26万元，用于3万吨大豆组织拉丝蛋白生产线建设项目、5000吨大豆 颗粒蛋白生产线建设项目、75T中温中压高效煤粉锅炉项目、补充流动资金。 索宝蛋白本次公开发行新股的发行费用合计3,958.59万元（不含税），其中承销及保荐费用2,735.85万 元。 中国经济网北京4月23日讯 索宝蛋白（603231）(603231.SH)昨日晚间披露公告，公司股东邦吉（上海） 管理有限公司(以下简称"上海邦吉")拟通过集中竞价或大宗交易方式减持公司股份合计不超过5,743 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603231 证券简称：索宝蛋白 公告编号：2025-003 宁波索宝蛋白科技股份有限公司 特定股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 特定股东持股的基本情况 截至本公告披露日，宁波索宝蛋白科技股份有限公司(以下简称"公司")的股东邦吉（上海）管理有限公 司(以下简称"上海邦吉")持有公司股份 7,179,715股，占公司总股本的3.75%。上述股份的来源均为公司 IPO 前取得的股份，已于2024年12月16日上市流通。上海邦吉无其他一致行动人。 ● 减持计划的主要内容 上海邦吉处于自身经营发展需要，拟通过集中竞价或大宗交易方式减持公司股份合计不超过5,743,615 股，即不超过公司总股本的3%。其中，拟通过集中竞价交易方式减持不超过1,914,500股，即不超过公 司总股本的1%；拟通过大宗交易方式减持不超过3,829,115股，即不超过公司总股本的2%。减持期间自 本减持计划公告披露之日起15个交易日 ...

证券代码：603231 证券简称：索宝蛋白 公告编号：2025-003 宁波索宝蛋白科技股份有限公司 减持计划的主要内容 上海邦吉处于自身经营发展需要，拟通过集中竞价或大宗交易方式减 持公司股份合计不超过 5,743,615 股，即不超过公司总股本的 3%。其中， 拟通过集中竞价交易方式减持不超过 1,914,500 股，即不超过公司总股本 的 1%；拟通过大宗交易方式减持不超过 3,829,115 股，即不超过公司总股 本的 2%。减持期间自本减持计划公告披露之日起 15 个交易日后（即 2025 年 5 月 20 日后）的 3 个月内，减持价格按市场价格确定。 若在减持计划期间公司有送股、配股等股份变动事项，减持股份数量 相应调整；若公司可转换公司债券转股、股权激励增发新股、非公开发行 股票等引起的股份变动事项，减持股份数量不做调整。 公司于 2025 年 4 月 22 日收到上海邦吉发来的《关于股份减持计划的 告知函》，现将有关情况公告如下： 1 上述减持主体无一致行动人。 特定股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的 ...

宁波索宝蛋白科技股份有限公司 第三届监事会第二次会议决议公告 证券代码：603231 证券简称：索宝蛋白 公告编号：2025-002 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 宁波索宝蛋白科技股份有限公司（以下简称"公司"）第三届监事会第二次会议 于 2024 年 12 月 28 日以邮件和书面送达等方式发出会议通知和资料，并于 2025 年 1 月 3 日在公司会议室以现场结合通讯表决方式召开会议。会议应出席监事 3 名，实际 出席 3 名，会议由监事会主席崔学英女士主持召开。董事会秘书列席本次会议。会议 召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合法、有效。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相关 公告。 特此公告。 宁波索宝蛋白科技股份有限公司监事会 2025 年 1 月 4 日 （一）审议通过《关于重新论证部分募集资金投资项目并继续实施的议案》 监事会认为：本次部分募集资金投资项目重新论证并继续实施，是公司根据项 目实施的实际情况 ...

东吴证券股份有限公司（以下简称"东吴证券"或"保荐人"）作为宁波索 宝蛋白科技股份有限公司（以下简称"索宝蛋白"）首次公开发行股票并在主 板上市的保荐人及持续督导机构，根据《证券发行上市保荐业务管理办法》 东吴证券股份有限公司 关于宁波索宝蛋白科技股份有限公司 2024 年度持续督导 工作现场检查报告 （一）保荐人 东吴证券股份有限公司 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所上市公司自律监管指引第 11 号——持续督导》等国家有关法律、法规和规 范性文件的要求，本着审慎和勤勉尽责的原则，对 2024 年度的规范运作情况进 行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （四）现场检查人员 庞家兴、祁俊伟、段钧脐 （二）保荐代表人 庞家兴、祁俊伟 （三）现场检查时间 2024 年 12 月 22 日至 2024 年 12 月 27 日 （五）现场检查内容 公司治理和内部控制、信息披露、独立性、与关联方的资金往来、募集资 金使用情况、关联交易、对外担保及重大对外投资情况、公司经营状况以及承 诺履行情况等。 （六）现场检查手段 1、与上市公司证券事 ...